HAYWARD, Calif.--(BUSINESS WIRE)--Dec 23, 2024-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field AblationTM (nano-PFA or nsPFATM) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about December 27, 2024, to redeem the first tranche of common stock warrants, redeemable by the Company if the Company’s stock trading price exceeds $16.50 for twenty consecutive trading days, that were issued as part of its July 3, 2024 rights offering which are still outstanding as of February 5, 2025 (the “Redemption Date”). These outstanding common stock warrants (the “150% Warrants”), which were issued in the Company’s 2024 rights offering (the “Rights Offering”), pursuant to the Company’s Registration Statement on Form S-3, as amended (File No. 333-278494), may be exercised by the holders thereof until 6:30 p.m., Eastern time, on the Redemption Date, at the exercise price of $11.00 per share of Company common stock, $0.001 par value per share. Any 150% Warrants not exercised before 6:30 p.m., Eastern time, on February 5, 2025, will be redeemed by the Company for $0.01 per 150% Warrant share (the “Redemption Price”). Under the terms of the 150% Warrants, the Company has the right to redeem the 150% Warrants (CUSIP # 74587B135) if the volume weighted average price (as defined therein, “VWAP”) exceeds $16.50 per share for twenty (20) consecutive trading days at least three months after the date that the 150% Warrants were issued. This requirement was met for each of the twenty consecutive trading days preceding December 23, 2024. Over this period, the Company had an average VWAP of $18.85. Any 150% Warrants that remain unexercised at 6:30 p.m., Eastern time, on the Redemption Date, will be void and no longer exercisable, and the holders of those 150% Warrants will be entitled to receive only the Redemption Price of $0.01 per 150% Warrant share. The second tranche of common stock warrants issued in the Rights Offering (the “200% Warrants”) are not being redeemed at this time. The Company received aggregate gross proceeds of $60 million from its Rights Offering, which was completed in July 2024, and the Company will receive an additional $66 million of gross proceeds, if all of the 150% Warrants and all of the 200% Warrants (collectively, the “Warrants”) are exercised prior to the Redemption Date. None of the Company, its board of directors or employees has made or is making any representation or recommendation to any holder of any Warrants as to whether to exercise or refrain from exercising any Warrants. A registration statement, as amended, relating to the Rights Offering was previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective on May 31, 2024. A prospectus relating to the offering was filed with the SEC on and supplemented on June 4, 2024 and is available on the SEC’s website. The Company will post a copy of the notice of redemption being sent to the holders of the 150% Warrants on its investor relations website at investors.pulsebiosciences.com . Questions concerning redemption and exercise of the 150% Warrants can be directed to Broadridge Corporate Issuer Solutions, LLC, Attn: BCIS Re-Organization Dept., P.O. Box 1317, Brentwood, NY 11717-0718, telephone number 888-789-8409 or to shareholder@broadridge.com . No Offer or Solicitation This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any offer of any of the Company’s securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFATM technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Florida and maintains its office in Hayward, California. Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s planned redemption of outstanding warrants, statements concerning its expected product development efforts, statements about its Nanosecond Pulsed Field Ablation (nsPFA) technology to non-thermally clear cells while sparing adjacent noncellular tissue, as well as statements concerning customer adoption and future use of the CellFX System to address a range of conditions such as atrial fibrillation. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available. View source version on businesswire.com : https://www.businesswire.com/news/home/20241223275716/en/ CONTACT: Investor Contacts: Pulse Biosciences Darrin Uecker, CTO or Kevin Danahy, CCO IR@pulsebiosciences.com or Gilmartin Group Philip Trip Taylor 415.937.5406 philip@gilmartinir.com KEYWORD: CALIFORNIA FLORIDA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES HEALTH PHARMACEUTICAL CARDIOLOGY SOURCE: Pulse Biosciences, Inc. Copyright Business Wire 2024. PUB: 12/23/2024 04:30 PM/DISC: 12/23/2024 04:30 PM http://www.businesswire.com/news/home/20241223275716/enTrump's TikTok love raises stakes in battle over app's fate
Trump Hints at His Next Legal Target in Truth Social PostDonald Trump Jr’s friends worried about ‘social climbing’ new girlfriend: report
The Detroit Lions will play without two high draft picks in rookie cornerbacks Terrion Arnold and Ennis Rakestraw Jr. while possibly getting back veteran Emmanuel Moseley against the host Indianapolis Colts on Sunday. Arnold was downgraded Saturday from questionable to out because of a groin injury. He was limited at practice on Thursday and participated in a full practice on Friday. The Lions drafted Arnold with the 24th overall pick of the 2024 NFL Draft out of Alabama. Arnold, 21, has started all 10 games and has 38 tackles and six passes defended. Rakestraw (hamstring) was placed on injured reserve after not practicing all week. He already had been ruled out for Sunday's game. Detroit picked Rakestraw in the second round (61st overall) out of Missouri. He has played in eight games and has six tackles. Rakestraw, 22, has played on 46 defensive snaps (8 percent) and 95 special teams snaps (42 percent). Moseley had full practice sessions all week and was activated from injured reserve on Saturday but was listed as questionable for Sunday. The 28-year-old is in his second season with Detroit and appeared in one game last season before going on IR in October 2023. He was placed on IR on Aug. 27 with a designation to return. Moseley played from 2018-22 for the San Francisco 49ers and had 162 tackles, four interceptions -- one returned for a touchdown -- and 33 passes defensed in 46 games (33 starts). Detroit elevated linebacker David Long on Saturday for game day. Long, 28, signed with the practice squad on Tuesday after the Miami Dolphins released him on Nov. 13. He had started six of eight games for the Dolphins this season and had 38 tackles. In other Lions news, the NFL fined wide receiver Jameson Williams $19,697 for unsportsmanlike conduct for making an obscene gesture during a touchdown celebration in last Sunday's 52-6 home win over the Jacksonville Jaguars, the NFL Network reported Saturday. Williams, 23, scored on a 65-yard pass from Jared Goff with 12:55 remaining in the third quarter. --Field Level MediaShares of food and beverage maker Kraft Heinz Co ($KHC) were down 0.3% on Monday as the company received a price target reduction by analyst firm Mizuho, with retail sentiment sliding. Mizuho lowered the firm's price target to $38 from $41 with an Outperform rating, The Fly.com reported, citing “continued uncertainty about demand related to GLP-1s and new regulatory concerns” that are likely to limit investor appetites to own the space in the near term. According to the firm, 2025 will begin with near 20-year valuation lows compared to the S&P 500 and has softer expectations for earnings per share as volumes and pricing power are constrained. Retail sentiment on the stock has turned bearish from neutral a week ago. Message volumes have remained low. According to Investing.com, the stock appeared undervalued as it reflected a significant retreat from its previous levels, showing a strong contrast from its track record and performance last year. In November, Kraft was reportedly facing a possible class action lawsuit about its Mac & Cheese product based on claims it misled consumers about containing no artificial flavors, preservatives, or dyes. "We stand fully behind our product and are proud of its quality," the company said. "We strongly believe that this lawsuit has no merit and look forward to our day in court." For updates and corrections, email newsroom[at]stocktwits[dot]com.<
This evening's episode of Casualty had audiences on the edge of their seat as two fresh characters made their debut, stirring up fears among loyal viewers. In a particularly dramatic and bloody new instalment, the storyline revolved around Dylan (portrayed by Will Beck) and Jodie (played by Anna Chell), with tensions flaring when she discovered that Dylan had agreed to mentor her only because her father had requested it. As they dined out to hash things over, their meal was shockingly interrupted by a vehicle smashing through the restaurant. The frantic driver turned out to be a husband in a desperate bid to get his pregnant wife to the hospital. Compelled by emergency, Dylan executed an impromptu C-section at the scene while the anxious father witnessed. Miraculously, the newborn was delivered safely, but the mother was not so fortunate; after being taken to the hospital, she suffered dual heart attacks and tragically passed away, leaving Dylan reeling from the outcome. Meanwhile, the introduction of two new paramedics sparked outrage among viewers due to their lackadaisical attitude towards their mentor, sparking speculation about possible repercussions for another beloved character, reports the Mirror . One fan took to social media, exasperated: "Don't like these new paramedics, but I didn't like the nurses when they first started so #Casualty," while another expressed annoyance: "Nah those 2 paramedics already doing my head in #Casualty." A third voiced their displeasure: "These two paramedics need to grow up! #casualty." A frustrated viewer of the show expressed their disappointment with the newcomers in the medical drama, saying: "The show's been crying out for some more more paramedics and we get these two ? Really #Casualty," while another feared potential cast changes: "Hope two new paramedics starting means doesn't mean one of the regulars is leaving #Casualty." Will Beck, known for portraying Dylan on the popular series, shared insights about the upcoming episodes, highlighting their intensity. He said: "The first thing that comes to mind is chaos, it's a real roller coaster ride. I think particularly for Jodie, it's a real opportunity for people to get to know her. "I think the thing that this box set does, is it goes to an emotional depth. Dylan strangely enough gets caught up in it because of the correlation between the situation that Jodie finds herself in." *Casualty airs on BBC One and BBC iPlayer.